

Perspectives

- New, Long-term Insights from the Adenoma Prevention with Celecoxib Trial on a Promising but Troubled Class of Drugs.**
Raymond N. DuBois285
Perspective on Bertagnolli et al., p. 310
- Mechanisms of Cyclooxygenase-2 Inhibition and Cardiovascular Side Effects—The Plot Thickens.**
Lawrence J. Marnett288
Perspective on Duffield-Lillico et al., p. 322
- Targeting Angiogenesis from Premalignancy to Metastases.**
Jennifer R. Grandis and Athanassios Argiris291
Perspective on Gandhi et al., p. 330
- Mechanistic Insights into Reducing the Weight of Breast Cancer.**
Stephen D. Hursting295
Perspective on Jiang et al., p. 338
- Cruciferous Vegetable Intake and Cancer Prevention: Role of Nutrigenetics.**
Christine B. Ambrosone and Li Tang298
Perspective on Navarro et al., p. 345

Review

- Energy Homeostasis and Cancer Prevention: The AMP-Activated Protein Kinase.**
Judith R. Fay, Vernon Steele and James A. Crowell301


Research Articles

- Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial.**
Monica M. Bertagnolli, Craig J. Eagle, Ann G. Zauber, Mark Redston, Aurora Breazna, KyungMann Kim, Jie Tang, Rebecca B. Rosenstein, Asad Umar, Donya Bagheri, Neal T. Collins, John Burn, Daniel C. Chung, Thomas Dewar, T. Raymond Foley, Neville Hoffman, Finlay Macrae, Ronald E. Pruitt, John R. Saltzman, Bruce Salzman, Thomas Sylwestrowicz, Ernest T. Hawk and for the Adenoma Prevention with Celecoxib Study Investigators310
- Levels of Prostaglandin E Metabolite and Leukotriene E₄ Are Increased in the Urine of Smokers: Evidence that Celecoxib Shunts Arachidonic Acid into the 5-Lipoxygenase Pathway.** Anna J. Duffield-Lillico, Jay O. Boyle, Xi Kathy Zhou, Aradhana Ghosh, Geera S. Butala, Kotha Subbaramaiah, Robert A. Newman, Jason D. Morrow, Ginger L. Milne and Andrew J. Dannenberg322
- Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis.** Leena Gandhi, Kate L. McNamara, Danan Li, Christa L. Borgman, Ultan McDermott, Kathelyn A. Brandstetter, Robert F. Padera, Lucian R. Chiriac, Jeffrey E. Settleman and Kwok-Kin Wong330
- Effects of Physical Activity and Restricted Energy Intake on Chemically Induced Mammary Carcinogenesis.** Weiqin Jiang, Zongjian Zhu and Henry J. Thompson338
- Cruciferous Vegetable Feeding Alters UGT1A1 Activity: Diet- and Genotype-Dependent Changes in Serum Bilirubin in a Controlled Feeding Trial.** Sandi L. Navarro, Sabrina Peterson, Chu Chen, Karen W. Makar, Yvonne Schwarz, Irena B. King, Shuying S. Li, Lin Li, Mark Kestin and Johanna W. Lampe345
- Dietary Sulforaphane-Rich Broccoli Sprouts Reduce Colonization and Attenuate Gastritis in *Helicobacter pylori*-Infected Mice and Humans.** Akinori Yanaka, Jed W. Fahey, Atsushi Fukumoto, Mari Nakayama, Souta Inoue, Songhua Zhang, Masafumi Tauchi, Hideo Suzuki, Ichinosuke Hyodo and Masayuki Yamamoto353

Liposomal Encapsulation of Deguelin: Evidence for Enhanced Antitumor Activity in Tobacco Carcinogen-Induced and Oncogenic K-ras-Induced Lung Tumorigenesis.	
Jong K. Woo, Dong Soon Choi, Hai T. Tran, Brian E. Gilbert, Waun Ki Hong and Ho-Young Lee	361
The Chemopreventive Agent Myoinositol Inhibits Akt and Extracellular Signal-Regulated Kinase in Bronchial Lesions from Heavy Smokers.	
Wei Han, Joell J. Gills, Regan M. Memmott, Stephen Lam and Phillip A. Dennis	370
Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies.	
Silvia Zanardi, Matteo Puntoni, Massimo Maffezzini, Roberto Bandelloni, Marco Mori, Alessandra Argusti, Fabio Campodonico, Laura Turbino, Daniela Branchi, Rodolfo Montironi and Andrea Decensi.....	377
ABT-510 Is an Effective Chemopreventive Agent in the Mouse 4-Nitroquinoline 1-Oxide Model of Oral Carcinogenesis.	
Rifat Hasina, Leslie E. Martin, Kristen Kasza, Colleen L. Jones, Asif Jalil and Mark W. Lingen.....	385
Chemoprevention of Human Actinic Keratoses by Topical DL-α-Tocopherol.	
Janet A. Foote, James R. Ranger-Moore, Janine G. Einspahr, Kathylynn Saboda, Jaime Kenyon, James Warneke, Richard C. Miller, Rayna Goldman, Min-Jian Xu, Denise J. Roe and David S. Alberts.....	394

About the Cover

The cover features a genetically engineered mouse (GEM; photo courtesy of Takeshi Shimamura). Genetic engineering in mice to conditionally activate oncogenic *Kras* with or without the conditional loss of the tumor suppressor *Lkb1* induces non-small-cell lung carcinogenesis. The *Lkb1/Kras*, *Kras* and other GEM models are valuable tools for preclinical tests of novel agents for the prevention and treatment of lung cancers. *Lkb1/Kras* mice are a novel model of metastatic lung cancer; lung cancer in *Kras* mice does not metastasize. These GEM models provide platforms to assess the impact of targeted agents on angiogenesis and the tumor-microenvironment interaction, which cannot be assessed or recapitulated easily in xenograft or in vitro models. Treatment or chemoprevention studies can be initiated and performed on these mice at specific time points in the genetically engineered oncogenic process. The multi-targeted (e.g., VEGFR) tyrosine kinase inhibitor sunitinib can repress and prevent tumors in both models, although it did not affect metastases in the *Lkb1/Kras* model. See articles by Gandhi *et al.* (beginning on page 330) and Grandis and Argiris (beginning on page 291) for more information.



Cancer Prevention Research

2 (4)

Cancer Prev Res 2009;2:285-400.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/2/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/2/4>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.